Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG103 Injection Monotherapy in Type 2 Diabetes Mellitus (Phase III)
CTR20240429Phase 3Completed
- Sponsor
- Tianshizhen Biotechnology
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of GX-G6 in type 2 diabetes mellitus (T2DM), sponsored by Tianshizhen Biotechnology. Started Feb 2024; status: completed.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20240429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240429.